Teresa Hernández-Iglesias

发表

Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients

Teresa Ribalta, Juan F. García, B. Meléndez, 2015, Journal of Neuro-Oncology.

Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks.

X. Chen, J. Montero, A. Pandiella, 2009, Blood.

Biomarker testing strategies in non-small cell lung cancer in the real-world setting: analysis of methods in the Prospective Central Lung Cancer Biomarker Registry (LungPath) from the Spanish Society of Pathology (SEAP)

Javier M. Martín-López, F. Rojo, T. Hernández-Iglesias, 2021, Journal of Clinical Pathology.

Dasatinib as a Bone-Modifying Agent: Anabolic and Anti-Resorptive Effects

A. Pandiella, F. Lee, A. Garcia-Gomez, 2012, PloS one.

Preclinical Activity of the Oral Proteasome Inhibitor MLN9708 in Myeloma Bone Disease

A. Berger, D. Chauhan, N. Raje, 2014, Clinical Cancer Research.

PreclinicalActivityoftheOralProteasomeInhibitorMLN9708 in Myeloma Bone Disease

J. Miguel, A. Berger, D. Chauhan, 2014 .

Molecular Classification Defines 4 Prognostically Distinct Glioma Groups Irrespective of Diagnosis and Grade

Juan F. García, B. Meléndez, J. Rey, 2015, Journal of neuropathology and experimental neurology.

In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma

P. Atadja, A. Pandiella, E. de Álava, 2010, Haematologica.

Neuronal Galectin‐4 is required for axon growth and for the organization of axonal membrane L1 delivery and clustering

Hans-Joachim Gabius, Silvia Velasco, Herbert Kaltner, 2013, Journal of neurochemistry.

Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks.

X. Chen, J. Montero, A. Pandiella, 2009, Blood.